Checkmate for Cancer: What Eli Lilly and Bayer Can Learn from Vidac Pharma

Eli Lilly: Metabolism as a Growth Driver

No company currently demonstrates more impressively than Eli Lilly just how efficient it can be to master metabolic processes. Through its innovations in the field of incretin mimetics, the US giant has revolutionized the treatment of obesity and diabetes and recorded a 56% jump in revenue to USD 19.8 billion in the first quarter. Eli Lilly shows how a deep understanding of enzyme interactions can turn entire markets upside down. Now this strategy is also finding its way into oncology. Eli Lilly is using its substantial cash reserves to build a bridge between metabolic medicine and cancer research through targeted acquisitions. The market, too, recognizes that correcting metabolic dysregulation is a powerful growth driver.

Bayer: Pressure to Transform Due to the Patent Cliff

The situation at Bayer illustrates that it is becoming increasingly crucial for established companies to be technologically flexible. The Leverkusen-based company faces the challenge of renewing its oncology pipeline following the expiration of key patents. The focus is on "first-in-class technologies" with revolutionary potential. For companies like Bayer, access to novel mechanisms of action that go beyond conventional chemotherapy is the only safeguard against the looming "patent cliff"—that is, the impending expiration of key patents and the resulting loss of stable revenue. The shift toward more precise, less toxic therapies is crucial for Bayer to continue playing a key role in the highly competitive oncology market.

Vidac Pharma and the Metabolic Revolution

The innovative biotech company Vidac Pharma is positioning itself in this promising niche. While Eli Lilly leverages metabolism for weight loss and Bayer is searching for new blockbusters, Vidac is regarded as an expert in the field of oncometabolics. The company aims to reverse the Warburg effect by detaching the enzyme hexokinase-2 (HK2) from the mitochondria of cancer cells. This detachment restores normal oxidative metabolism and reactivates the cancer cell's natural ability to initiate programmed cell death. Vidac thus targets a fundamental mechanism that works beyond oncology in other fields, such as dermatology. This demonstrates the versatility of Vidac's approach and reduces shareholder risk.

Since hexokinase-2 also plays a central role in inflammatory skin diseases such as psoriasis, Vidac is targeting not only oncology but also a market estimated to exceed USD 39 billion by 2030. Vidac has recently initiated new in vivo models to demonstrate the superiority of its mechanism of action over conventional therapies. The company's conviction in the technology is also reflected in a USD 1.5 million investment by management to support the next clinical phase without external financing, thereby avoiding near-term shareholder dilution. This was achieved by management selling their personal shareholdings, with the proceeds used to fund the company's development activities. While this approach is unconventional, it may help avoid raising capital at depressed share price levels. Such signals can, in some cases, strengthen market confidence in both management and the company.

Conclusion: Vidac Pharma occupies a promising niche

While some market participants are still eyeing the next blockbuster that tackles cancer with aggressive methods, Vidac Pharma is advancing its smart and, above all, versatile technology centred on cellular metabolism. GBC analysts view Vidac as clearly undervalued, with a price target of EUR 4.30, which, given its current market capitalization of around EUR 30 million, points to significant upside potential.

At a time when new approaches in biotechnology are in high demand, and companies like Bayer must replace expiring patents, Vidac is positioning itself as a promising problem-solver. Since reversing the Warburg effect shows promise in various areas, Vidac shareholders have several irons in the fire. Although the stock is considered speculative given its stage of development and low market capitalization, Vidac occupies a promising niche. Added to this is management's confidence in its own research capabilities. Vidac Pharma's stock has been trading sideways in recent weeks—any clinical progress could get the small-cap back on track and generate strong returns.